China Pharma Holdings (01093.HK) 2025 Annual Revenue of 26.006 Billion Yuan, Net Profit Reaches 3.882 Billion Yuan

NightAirdropper · 2026-03-25T05:50:37+00:00

Shijiazhuang Pharma Group's profit attributable to shareholders for the 2025 financial year was 3.882 billion yuan, with revenue of 26.006 billion yuan, representing a year-over-year decrease of 10.4%. The company is advancing innovation drug development and technology applications through strengthened R&D and digital transformation initiatives, continuously improving research and development efficiency.

NightAirdropper

2026-03-25 05:50:37

Abstract generation in progress

Guotong Hui March 25 — CSPC Pharmaceutical Group (01093.HK) announced its annual results. For the year ending December 31, 2025, the company’s attributable net profit was RMB 3.882 billion, compared to RMB 4.328 billion in 2024. Excluding fair value changes of financial assets at fair value through profit or loss and share-based employee compensation expenses, the basic attributable profit for shareholders was RMB 3.534 billion, down from RMB 4.683 billion in 2024. The board recommends a final dividend of HKD 0.15 per share for 2025.

Annual revenue was RMB 26.006 billion, a decrease of 10.4% from RMB 29.009 billion in 2024, mainly due to the inclusion of Domesol® and Jinyouli® in centralized procurement. Gross profit margin slightly declined by 4.4 percentage points to 65.6%. The finished drug business revenue was RMB 20.584 billion (including licensing fee income of RMB 1.789 billion), down 13.3% year-over-year; raw material product sales reached RMB 3.657 billion, an increase of 2.1%; functional foods and other business sales were RMB 1.765 billion, up 4.5%, mainly driven by steady growth in sales of Guoweikang during the year.

The group continues to promote the implementation of its innovation pipeline, strengthen key core technology breakthroughs, and leverage two national key laboratories to focus on applied basic research and overcoming common technical challenges. It actively explores frontier technologies such as cell therapy and nucleic acid therapy, advancing the development of autologous CAR-T candidate SYS6055, tumor therapeutic vaccines, small nucleic acid drugs, and other products, further enhancing its innovative product portfolio and demonstrating strong R&D capabilities. Additionally, in digitalization, the group actively deepens the application of AI in drug R&D, expanding AI-assisted research platforms to empower innovation and accelerate intelligent transformation, continuously improving R&D efficiency and results translation.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.